Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Acella Pharmaceuticals, LLC
EIR
•Acella Pharmaceuticals, LLC•January 7, 2020

Acella Pharmaceuticals, LLC – FDA EIR, Jan 7, 2020

Record Details

An FDA inspection of Acella Pharmaceuticals, LLC, an own-label distributor of pharmaceutical and dietary supplement products, occurred from December 17, 2019, to January 7, 2020, in Alpharetta, GA. The inspection, conducted under drug manufacturing compliance programs, identified significant violations of current Good Manufacturing Practices (cGMP) regulations, particularly 21 CFR 211.22(a). The primary issues highlighted in the FDA-483 included the absence of an adequate quality control unit. Acella failed to ensure product quality upon release, merely reviewing contractor documents for NP Thyroid without verifying test data. The firm also inadequately investigated over 80 customer complaints concerning "odor" or "taste" of NP Thyroid tablets, failing to include all supply chain parties or determine root causes. Furthermore, over 74% of complaints lacked lot numbers and received insufficient investigation from both the contract manufacturer and Acella. A critical finding was the deficiency in complaint procedures, specifically regarding adverse event reporting. Numerous serious patient experiences, such as heart palpitations and severe TSH level changes, were improperly classified as "non-serious, unexpected" by a third-party, leading to underreporting to the FDA. Acella also neglected to reply to complainants, even when requested, for hundreds of cases, and this requirement was absent from their procedures. Additionally, a verbal observation noted the lack of temperature control during the transportation of drug product components and finished goods. Acella's Senior Vice President promised corrective actions and a written response to address these systemic issues, which span quality control, complaint handling, adverse event reporting, and supply chain oversight.

Company
Acella Pharmaceuticals, LLC
Inspection date
January 7, 2020
Product type
Dietary Supplements
Office
Atlanta District Office
People
  • Veronica Fuentes (Pharmaceutical Specialist/ Investigator )
  • Gideon N. Esuzor (Investigator)
View Company Profile

ID · f46fcdb5-67a6-4e51-9e72-b0ad0da9b746

Violation Codes5
21 CFR 820.19821 CFR 21121 CFR 211.198(b)(1)21 CFR 211.198(a)21 CFR 211.22(a)

Full citation text and observation details available on the Dashboard.

Other documents for Acella Pharmaceuticals, LLC
  • 483 - 2024-12-18December 18, 2024
  • 483 - 2023-02-10February 10, 2023
  • 483 - 2021-09-17September 17, 2021
  • WARNING_LETTER - 2020-01-07January 7, 2020
  • 483 - 2020-01-07January 7, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Acella Pharmaceuticals, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.